{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:57:46Z","timestamp":1790855866259,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11899-023-00692-w","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T16:30:49Z","timestamp":1680712249000},"page":"83-88","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications"],"prefix":"10.1007","volume":"18","author":[{"given":"Daniel E.","family":"Luna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-5330","authenticated-orcid":false,"given":"Michi M.","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"692_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, Jaffe ES. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703.","journal-title":"Blood"},{"key":"692_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12102921","volume":"12","author":"G Dobos","year":"2020","unstructured":"Dobos G, Pohrt A, Ram-Wolff C, Lebb\u00e9 C, Bouaziz JD, Battistella M, Bagot M, de Masson A. Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients. Cancers (Basel). 2020;12:1\u201314.","journal-title":"Cancers (Basel)"},{"key":"692_CR3","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/bloodadvances.2020001441","volume":"4","author":"A Iyer","year":"2020","unstructured":"\u2022 Iyer A, Hennessey D, O\u2019Keefe S, Patterson J, Wang W, Wong GKS, Gniadecki R. Branched evolution and genomic intratumor heterogeneity in the pathogenesis of cutaneous T-cell lymphoma. Blood Adv. 2020;4:2489\u2013500. (Study supporting a heterogeneous mutational subclonal model of pathogenesis of a mycosis fungoides.)","journal-title":"Blood Adv"},{"key":"692_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3324\/haematol.2018.197152","volume":"104","author":"L Prieto-Torres","year":"2019","unstructured":"Prieto-Torres L, Rodriguez-Pinilla SM, Onaindia A, Ara M, Requena L, Piris M. CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies. Haematologica. 2019;104:226\u201335.","journal-title":"Haematologica"},{"key":"692_CR5","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1158\/2159-8290.CD-21-1207","volume":"12","author":"X Song","year":"2022","unstructured":"\u2022\u2022 Song X, Chang S, Seminario-Vidal L, et al. Genomic and single-cell landscape reveals novel drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma. Cancer Discov. 2022;12:1294\u2013313. (Multiomics data of a large series of transformed CTCL highlighting new key novel drivers including the importance of the UV marker signature 7.)","journal-title":"Cancer Discov"},{"key":"692_CR6","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen E, ISCL\/EORTC for the, Vonderheid E, et al. Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Ca. Blood. 2007;110:1713\u201322.","journal-title":"Blood"},{"key":"692_CR7","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","volume":"132","author":"YH Kim","year":"1996","unstructured":"Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides: a long-term outcome analysis. Arch Dermatol. 1996;132:1309\u201313.","journal-title":"Arch Dermatol"},{"key":"692_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/archderm.139.7.857","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139:857\u201366.","journal-title":"Arch Dermatol"},{"key":"692_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, Desantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443\u201359.","journal-title":"CA Cancer J Clin"},{"key":"692_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jid.2019.07.712","volume":"140","author":"A Mourad","year":"2020","unstructured":"Mourad A, Gniadecki R. Overall survival in mycosis fungoides: a systematic review and meta-analysis. J Invest Dermatol. 2020;140:495-497.e5.","journal-title":"J Invest Dermatol"},{"key":"692_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jaad.2012.04.043","volume":"67","author":"AW Kubica","year":"2012","unstructured":"Kubica AW, Davis MDP, Weaver AL, Killian JM, Pittelkow MR. S\u00e9zary syndrome: a study of 176 patients at Mayo Clinic. J Am Acad Dermatol. 2012;67:1189\u201399.","journal-title":"J Am Acad Dermatol"},{"key":"692_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13045-020-01006-w","volume":"13","author":"K I\u017cykowska","year":"2020","unstructured":"I\u017cykowska K, Rassek K, Korsak D, Przybylski GK. Novel targeted therapies of T cell lymphomas. J Hematol Oncol. 2020;13:176.","journal-title":"J Hematol Oncol"},{"key":"692_CR13","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood.2019002516","volume":"134","author":"A Iyer","year":"2019","unstructured":"Iyer A, Hennessey D, O\u2019Keefe S, Patterson J, Wang W, Wong GKS, Gniadecki R. Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma. Blood. 2019;134:1517\u201327.","journal-title":"Blood"},{"key":"692_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28799-3","author":"X Liu","year":"2022","unstructured":"\u2022 Liu X, Jin S, Hu S, et al. Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma. Nat Commun. 2022. https:\/\/doi.org\/10.1038\/s41467-022-28799-3. (Study supporting a monoclonal origin model of CTCL based on varied T-cell subsets within MF patients.)","journal-title":"Nat Commun"},{"key":"692_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030328","author":"P Licht","year":"2022","unstructured":"Licht P, Mail\u00e4nder V. Transcriptional heterogeneity and the microbiome of cutaneous T-cell lymphoma. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11030328.","journal-title":"Cells"},{"key":"692_CR16","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","volume":"116","author":"JJ Campbell","year":"2010","unstructured":"Campbell JJ, Clark RA, Watanabe R, Kupper TS. S\u00e9zary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116:767.","journal-title":"Blood"},{"key":"692_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/cyto.b.21738","volume":"96","author":"P Horna","year":"2019","unstructured":"\u2022 Horna P, Moscinski LC, Sokol L, Shao H. Na\u00efve\/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: putative cell of origin overlaps disease classification. Cytometry B Clin Cytom. 2019;96:234. (Study supporting that both S\u00e9zary syndrome and mycosis fungoides can have phenotypic features of any of the major na\u00efve\/memory T-cell subsets which can functionally change with disease progression.)","journal-title":"Cytometry B Clin Cytom"},{"key":"692_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94\u2013101.","journal-title":"Nature"},{"key":"692_CR19","unstructured":"\u2022 Jones CL, Degasperi A, Grandi V, Amarante TD, England G, Consortium R, Mitchell TJ, Nik-Zainal S, Whittaker SJ (2021) Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma. Sci Reports | 11:3962. (Report on the UV marker signature 7's high mutational burden in CTCL.)."},{"issue":"25","key":"692_CR20","first-page":"221","volume":"252","author":"LD Trucco","year":"2018","unstructured":"Trucco LD, Mundra PA, Hogan K, et al. (2018) Ultraviolet radiation\u2013induced DNA damage is prognostic for outcome in melanoma. Nat Med. 2018;252(25):221\u20134.","journal-title":"Nat Med"},{"key":"692_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","volume":"74","author":"EA Olsen","year":"2016","unstructured":"Olsen EA, Hodak E, Anderson T, Carter JB, Henderson M, Cooper K, Lim HW. Guidelines for phototherapy of mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2016;74:27\u201358.","journal-title":"J Am Acad Dermatol"},{"key":"692_CR22","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/jnci\/90.17.1278","volume":"90","author":"RS Stern","year":"1998","unstructured":"Stern RS, Liebman EJ, V\u00e4kev\u00e4 L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst. 1998;90:1278\u201384.","journal-title":"J Natl Cancer Inst"},{"key":"692_CR23","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/j.1365-2133.2008.08776.x","volume":"159","author":"RMR Hearn","year":"2008","unstructured":"Hearn RMR, Kerr AC, Rahim KF, Ferguson J, Dawe RS. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol. 2008;159:931\u20135.","journal-title":"Br J Dermatol"},{"key":"692_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1080\/09546634.2017.1365113","volume":"29","author":"JW Hoot","year":"2018","unstructured":"Hoot JW, Wang L, Kho T, Akilov OE. The effect of phototherapy on progression to tumors in patients with patch and plaque stage of mycosis fungoides. J Dermatolog Treat. 2018;29:272.","journal-title":"J Dermatolog Treat"},{"key":"692_CR25","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30:R921\u20135.","journal-title":"Curr Biol"},{"issue":"8","key":"692_CR26","first-page":"1","volume":"81","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic D, Song M, Wang L. Zhang Y (2020) Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark Res. 2020;81(8):1\u201316.","journal-title":"Biomark Res"},{"key":"692_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/J.SEMCANCER.2021.12.003","author":"K Patil","year":"2021","unstructured":"Patil K, Kuttikrishnan S, Khan AQ, Ahmad F, Alam M, Buddenkotte J, Ahmad A, Steinhoff M, Uddin S. Molecular pathogenesis of cutaneous t cell lymphoma: role of chemokines, cytokines, and dysregulated signaling pathways. Semin Cancer Biol. 2021. https:\/\/doi.org\/10.1016\/J.SEMCANCER.2021.12.003.","journal-title":"Semin Cancer Biol"},{"key":"692_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00281-016-0594-9","volume":"39","author":"T Krejsgaard","year":"2017","unstructured":"Krejsgaard T, Lindahl LM, Mongan NP, Wasik MA, Litvinov IV, Iversen L, Langhoff E, Woetmann A, Odum N. Malignant inflammation in cutaneous T-cell lymphoma\u2014a hostile takeover. Semin Immunopathol. 2017;39:269.","journal-title":"Semin Immunopathol"},{"key":"692_CR29","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/0190-9622(95)90067-5","volume":"32","author":"RT Hoppe","year":"1995","unstructured":"Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol. 1995;32:448\u201353.","journal-title":"J Am Acad Dermatol"},{"key":"692_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1365-2567.2006.02452.x","volume":"120","author":"H Huang","year":"2007","unstructured":"Huang H, Hao S, Li F, Ye Z, Yang J, Xiang J. CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology. 2007;120:148.","journal-title":"Immunology"},{"key":"692_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.immuni.2005.02.003","volume":"22","author":"A Corthay","year":"2005","unstructured":"Corthay A, Skovseth DK, Lundin KU, R\u00f8sj\u00f8 E, Omholt H, Hofgaard PO, Haraldsen G, Bogen B. Primary antitumor immune response mediated by CD4+ T cells. Immunity. 2005;22:371\u201383.","journal-title":"Immunity"},{"key":"692_CR32","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0092-8674(00)80702-3","volume":"100","author":"SJ Szabo","year":"2000","unstructured":"Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000;100:655\u201369.","journal-title":"Cell"},{"key":"692_CR33","first-page":"74","volume":"12","author":"J Lee","year":"2021","unstructured":"Lee J, Lozano-Ruiz B, Yang FM, Fan DD, Shen L, Gonz\u00e1lez-Navajas JM. The multifaceted role of Th1, Th9, and Th17 cells in immune checkpoint inhibition therapy. Front Immunol. 2021;12:74.","journal-title":"Front Immunol"},{"key":"692_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/1523-1747.ep12388985","volume":"103","author":"G Saed","year":"1994","unstructured":"Saed G, Fivenson DP, Naidu Y, Nickoloff BJ. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome express a Th2-type profile. J Invest Dermatol. 1994;103:29\u201333.","journal-title":"J Invest Dermatol"},{"key":"692_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/1523-1747.ep12611877","volume":"99","author":"BR Vowels","year":"1992","unstructured":"Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol. 1992;99:90\u20134.","journal-title":"J Invest Dermatol"},{"key":"692_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1046\/j.1365-2249.1998.00599.x","volume":"112","author":"N Seo","year":"1998","unstructured":"Seo N, Tokura Y, Matsumoto K, Furukawa F, Takigawa M. Tumour-specific cytotoxic T lymphocyte activity in Th2-type S\u00e9zary syndrome: its enhancement by interferon-gamma (IFN-\u03b3) and IL-12 and fluctuations in association with disease activity. Clin Exp Immunol. 1998;112:403.","journal-title":"Clin Exp Immunol"},{"key":"692_CR37","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/bjd.16237","volume":"178","author":"R Nakajima","year":"2018","unstructured":"Nakajima R, Miyagaki T, Hirakawa M, et al. Interleukin-25 is involved in cutaneous T-cell lymphoma progression by establishing a T helper 2-dominant microenvironment. Br J Dermatol. 2018;178:1373\u201382.","journal-title":"Br J Dermatol"},{"key":"692_CR38","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3389\/fcell.2020.00851","volume":"8","author":"V Stolearenco","year":"2020","unstructured":"Stolearenco V, Namini MRJ, Hasselager SS, Gluud M, Buus TB, Willerslev-Olsen A, \u00d8dum N, Krejsgaard T. Cellular interactions and inflammation in the pathogenesis of cutaneous t-cell lymphoma. Front Cell Dev Biol. 2020;8:851.","journal-title":"Front Cell Dev Biol"},{"key":"692_CR39","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.1200\/JCO.2001.19.23.4322","volume":"19","author":"MH Vermeer","year":"2001","unstructured":"Vermeer MH, Doorn RV, Dukers D, Bekkenk MW, Meijer CJLM, Willemze R. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol. 2001;19:4322\u20139.","journal-title":"J Clin Oncol"},{"key":"692_CR40","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","volume":"19","author":"E Guenova","year":"2013","unstructured":"Guenova E, Watanabe R, Teague JE, et al. Th2 cytokines from malignant cells suppress Th1 responses and enforce a global Th2 bias in leukemic cutaneous T cell lymphoma. Clin Cancer Res. 2013;19:3755.","journal-title":"Clin Cancer Res"},{"key":"692_CR41","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan Y, Yu Y, Wang X, Zhang T. Tumor-associated macrophages in tumor immunity. Front Immunol. 2020;11:3151.","journal-title":"Front Immunol"},{"key":"692_CR42","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1084\/jem.20170277","volume":"216","author":"M Rapp","year":"2019","unstructured":"Rapp M, Wintergerst MWM, Kunz WG, et al. CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes. J Exp Med. 2019;216:1170\u201381.","journal-title":"J Exp Med"},{"key":"692_CR43","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3389\/fonc.2019.00907","volume":"9","author":"K Tanita","year":"2019","unstructured":"Tanita K, Fujimura T, Sato Y, et al. Bexarotene reduces production of CCL22 from tumor-associated macrophages in cutaneous T-cell lymphoma. Front Oncol. 2019;9:907.","journal-title":"Front Oncol"},{"key":"692_CR44","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1046\/j.1523-1747.2002.19610.x","volume":"119","author":"K Ferenczi","year":"2002","unstructured":"Ferenczi K, Fuhlbrigge RC, Pinkus JL, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119:1405\u201310.","journal-title":"J Invest Dermatol"},{"key":"692_CR45","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/eji.202049043","volume":"51","author":"JP Nicolay","year":"2021","unstructured":"Nicolay JP, Albrecht JD, Alberti-Violetti S, Berti E. CCR4 in cutaneous T-cell lymphoma: therapeutic targeting of a pathogenic driver. Eur J Immunol. 2021;51:1660\u201371.","journal-title":"Eur J Immunol"},{"key":"692_CR46","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","volume":"19","author":"YH Kim","year":"2018","unstructured":"Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1192\u2013204.","journal-title":"Lancet Oncol"},{"key":"692_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2015.1011524","volume":"4","author":"X Ni","year":"2015","unstructured":"Ni X, Langridge T, Duvic M. Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab. Oncoimmunology. 2015;4:1\u20132.","journal-title":"Oncoimmunology"},{"key":"692_CR48","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1182\/blood.2021014468","volume":"139","author":"S Beygi","year":"2022","unstructured":"Beygi S, Duran GE, Fernandez-Pol S, Rook AH, Kim YH, Khodadoust MS. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma. Blood. 2022;139:3732\u20136.","journal-title":"Blood"},{"key":"692_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14099","volume":"33","author":"K Ohuchi","year":"2020","unstructured":"Ohuchi K, Fujimura T, Lyu C, Amagai R, Muto Y, Aiba S. Serum CCL22 levels decreased in parallel with disease activity in CCR4-positive mycosis fungoides treated with mogamulizumab. Dermatol Ther. 2020;33: e14099.","journal-title":"Dermatol Ther"},{"issue":"18","key":"692_CR50","first-page":"99","volume":"182","author":"X Chen","year":"2018","unstructured":"Chen X. Song E (2018) Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2018;182(18):99\u2013115.","journal-title":"Nat Rev Drug Discov"},{"key":"692_CR51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","volume":"121","author":"A Orimo","year":"2005","unstructured":"Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion. Cell. 2005;121:335\u201348.","journal-title":"Cell"},{"key":"692_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/BCR138","author":"A Olumi","year":"1999","unstructured":"Olumi A, Grossfeld G, Hayward S, Carroll P, Cunha G, Hein P, Tlsty T. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999. https:\/\/doi.org\/10.1186\/BCR138.","journal-title":"Cancer Res"},{"issue":"4","key":"692_CR53","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrc1456","volume":"410","author":"CH Heldin","year":"2004","unstructured":"Heldin CH, Rubin K, Pietras K. \u00d6stman A (2004) High interstitial fluid pressure \u2014 an obstacle in cancer therapy. Nat Rev Cancer. 2004;410(4):806\u201313.","journal-title":"Nat Rev Cancer"},{"key":"692_CR54","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.4049\/jimmunol.1402610","volume":"194","author":"T-P Chang","year":"2015","unstructured":"Chang T-P, Poltoratsky V, Vancurova I. Bortezomib inhibits expression of TGF-\u03b21, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells. J Immunol. 2015;194:2942\u201353.","journal-title":"J Immunol"},{"key":"692_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-021-08142-7","volume-title":"Normal and cancer fibroblasts differentially regulate TWIST1","author":"SJ Mehdi","year":"2021","unstructured":"Mehdi SJ, Moerman-Herzog A, Wong HK. Normal and cancer fibroblasts differentially regulate TWIST1. BMC Cancer: TOX and cytokine gene expression in cutaneous T-cell lymphoma; 2021. https:\/\/doi.org\/10.1186\/S12885-021-08142-7."},{"key":"692_CR56","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jid.2020.06.034","volume":"141","author":"A Aronovich","year":"2021","unstructured":"Aronovich A, Moyal L, Gorovitz B, et al. Cancer-associated fibroblasts in mycosis fungoides promote tumor cell migration and drug resistance through CXCL12\/CXCR4. J Invest Dermatol. 2021;141:619-627.e2.","journal-title":"J Invest Dermatol"},{"key":"692_CR57","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.4161\/cbt.6.11.4874","volume":"6","author":"K Narra","year":"2007","unstructured":"Narra K, Mullins SR, Lee HO, et al. Phase II trial of single agent Val-boroPro (Talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007;6:1691\u20139.","journal-title":"Cancer Biol Ther"},{"key":"692_CR58","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.3892\/mmr.2016.4868","volume":"13","author":"M Li","year":"2016","unstructured":"Li M, Li M, Yin T, Shi H, Wen Y, Zhang B, Chen M, Xu G, Ren K, Wei Y. Targeting of cancer-associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment. Mol Med Rep. 2016;13:2476\u201384.","journal-title":"Mol Med Rep"},{"key":"692_CR59","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jama.1992.03480100060031","volume":"267","author":"PI Axelrod","year":"1992","unstructured":"Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and S\u00e9zary syndrome. JAMA. 1992;267:1354\u20138.","journal-title":"JAMA"},{"key":"692_CR60","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood.V89.1.32.32_32_40","volume":"89","author":"CM Jackow","year":"1997","unstructured":"Jackow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V\u03b2 gene expansion. Blood. 1997;89:32\u201340.","journal-title":"Blood"},{"key":"692_CR61","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/bjd.17073","volume":"179","author":"R Blaizot","year":"2018","unstructured":"Blaizot R, Ouattara E, Fauconneau A, Beylot-Barry M, Pham-Ledard A. Infectious events and associated risk factors in mycosis fungoides\/S\u00e9zary syndrome: a retrospective cohort study. Br J Dermatol. 2018;179:1322\u20138.","journal-title":"Br J Dermatol"},{"key":"692_CR62","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S1473-3099(13)70036-7","volume":"13","author":"CDJ den Heijer","year":"2013","unstructured":"den Heijer CDJ, van Bijnen EME, Paget WJ, Pringle M, Goossens H, Bruggeman CA, Schellevis FG, Stobberingh EE. Prevalence and resistance of commensal Staphylococcus aureus, including meticillin-resistant S aureus, in nine European countries: a cross-sectional study. Lancet Infect Dis. 2013;13:409\u201315.","journal-title":"Lancet Infect Dis"},{"key":"692_CR63","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1086\/499632","volume":"193","author":"MJ Kuehnert","year":"2006","unstructured":"Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001\u20132002. J Infect Dis. 2006;193:172\u20139.","journal-title":"J Infect Dis"},{"key":"692_CR64","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1365-2133.2008.08612.x","volume":"159","author":"R Talpur","year":"2008","unstructured":"Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and S\u00e9zary syndrome. Br J Dermatol. 2008;159:105\u201312.","journal-title":"Br J Dermatol"},{"key":"692_CR65","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1641387","author":"E Bl\u00fcmel","year":"2019","unstructured":"\u2022 Bl\u00fcmel E, Willerslev-Olsen A, Gluud M, et al. Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4+ T cells in cutaneous T-cell lymphoma. Oncoimmunology. 2019. https:\/\/doi.org\/10.1080\/2162402X.2019.1641387. (Staphylococcus aureus can potentially select for more malignant CD4+ T-cells in S\u00e9zary syndrome patients via downregulation of ADAM10 which confers higher resistance to alpha-toxin.)","journal-title":"Oncoimmunology"},{"key":"692_CR66","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.4161\/15384101.2014.965061","volume":"13","author":"E Netchiporouk","year":"2014","unstructured":"Netchiporouk E, Litvinov IV, Moreau L, Gilbert M, Sasseville D, Duvic M. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle. 2014;13:3331\u20135.","journal-title":"Cell Cycle"},{"key":"692_CR67","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1182\/blood-2019-125017","volume":"134","author":"AJ Moskowitz","year":"2019","unstructured":"Moskowitz AJ, Ghione P, Jacobsen ED, et al. Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma. Blood. 2019;134:4019\u20134019.","journal-title":"Blood"},{"key":"692_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2020.100832","volume":"24","author":"IJ Brouwer","year":"2020","unstructured":"Brouwer IJ, Out-Luiting JJ, Vermeer MH, Tensen CP. Cucurbitacin E and I target the JAK\/STAT pathway and induce apoptosis in S\u00e9zary cells. Biochem Biophys Reports. 2020;24: 100832.","journal-title":"Biochem Biophys Reports"},{"key":"692_CR69","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.3324\/haematol.2015.132837","volume":"100","author":"C P\u00e9rez","year":"2015","unstructured":"P\u00e9rez C, Gonz\u00e1lez-Rinc\u00f3n J, Onaindia A, et al. Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. Haematologica. 2015;100:e450\u20133.","journal-title":"Haematologica"},{"key":"692_CR70","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jid.2017.10.028","volume":"138","author":"MH Fanok","year":"2018","unstructured":"Fanok MH, Sun A, Fogli LK, et al. Role of dysregulated cytokine signaling and bacterial triggers in the pathogenesis of cutaneous T-cell lymphoma. J Invest Dermatol. 2018;138:1116\u201325.","journal-title":"J Invest Dermatol"},{"key":"692_CR71","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1182\/blood-2015-08-662353","volume":"127","author":"A Willerslev-Olsen","year":"2016","unstructured":"Willerslev-Olsen A, Krejsgaard T, Lindahl LM, et al. Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood. 2016;127:1287\u201396.","journal-title":"Blood"},{"issue":"19","key":"692_CR72","first-page":"1","volume":"191","author":"S Zou","year":"2020","unstructured":"Zou S, Tong Q, Liu B, Huang W, Tian Y. Fu X (2020) Targeting STAT3 in cancer immunotherapy. Mol Cancer. 2020;191(19):1\u201319.","journal-title":"Mol Cancer"},{"key":"692_CR73","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1182\/blood.2018888107","volume":"134","author":"LM Lindahl","year":"2019","unstructured":"Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR, et al. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood. 2019;134:1072.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00692-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-023-00692-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-023-00692-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T09:42:49Z","timestamp":1682588569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-023-00692-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["692"],"URL":"https:\/\/doi.org\/10.1007\/s11899-023-00692-w","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"27 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Daniel Luna declares that he has no conflict of interest. Michi Shinohara MD is a member of the NCCN T-cell Lymphoma Panel, as well as a board member of the US Cutaneous Lymphoma Consortium.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}